1.Wilson, J.M.G. and Jungner, G. Principles and practice of screening for disease. WHO Chronicle. Geneva: World Health Organization. 1968, 22(11):473. Public Health Papers, #34.
2.National Cancer Institute. Surveillance, Epidemiology, and End Results program: Cancer statistics. Available at: www.seer.cancer.gov. Retrieved August 29, 2015.
3.Jenabi, E. and Poorolajal, J. The effect of body mass index on endometrial cancer: A meta-analysis. Public Health. May 27, 2015. doi: 10.1016/j.puhe.2015.04.017 [Epub ahead of print].
4.American College of Obstetricians and Gynecologists. Tamoxifen and uterine cancer. Committee Opinion No. 601. Obstet Gynecol. 2014, 123:1394–7.
5.Wells, G.A., Cranney, A., Peterson, J. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008, (1):CD001155. doi: 10.1002/14651858.CD001155.pub2.
6.Taylor, F., Huffman, M.D., Macedo, A.F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013, (1):CD004816. doi: 10.1002/14651858.CD004816.pub5.
8.Lindson-Hawley, N., Thompson, T.P., and Begh, R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015, (3):CD006936. doi: 10.1002/14651858.CD006936.pub3.
9.Stead, L.F. and Lancaster, T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012, (10):CD008286. doi: 10.1002/14651858.CD008286.pub2.
10.Smedslund, G., Berg, R.C., Hammerstrøm, K.T. et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011, (5):CD008063. doi: 10.1002/14651858.CD008063.pub2.
13.Norton, M.E., Jacobsson, B., Swamy, G.K. et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015, 372(17):1589–97.
14.American College of Obstetricians and Gynecologists. Cell-free DNA screening for fetal aneuploidy. Committee Opinion No. 640. Obstet Gynecol. 2015, 126:e31–7.
15.Humphrey, L.L., Helfand, M., Chan, B.K., and Woolf, S.H. Breast cancer screening: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002, 137:347–60.
16.Mayrand, M.H., Duarte-Franco, E., Rodrigues, I. et al.; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med. 2007, 357(16):1579–88.
17.Gilbody, S., Sheldon, T., and House, A. Screening and case-finding instruments for depression: A meta-analysis. CMAJ. 2008, 178(8):997–1003.
18.Malkasian, G.D. Jr., Knapp, R.C., Lavin, P.T. et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988, 159(2):341–6.
19.Im, S.S., Gordon, A.N., Buttin, B.M. et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol. 2005, 105(1):35–41.
21.American College of Obstetricians and Gynecologists. Screening for cervical cancer. Practice Bulletin No. 131. Obstet Gynecol. 2012, 120:1222–38.
22.Sasieni, P., Castanon, A., and Cuzick, J. Effectiveness of cervical screening with age: Population based case–control study of prospectively recorded data [published erratum appears in BMJ 2009;339: b3115]. BMJ. 2009, 339:b2968.
24.Sagara, Y., Mallory, M.A., Wong, S. et al. Survival benefit of breast surgery for low-grade ductal carcinoma in situ: A population-based cohort study. JAMA Surg. 2015, 150(8):739–45.
27.American College of Obstetricians and Gynecologists. Hereditary breast and ovarian cancer syndrome. Practice Bulletin No. 103. Obstet Gynecol. 2009, 113:957–66.